BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

6:05 PM
 | 
Feb 25, 2010
 |  BC Extra  |  Clinical News

Avastin data for ovarian cancer

Roche (SIX:ROG; OTCQX:RHHBY) and its Genentech Inc. unit reported top-line data from the Phase III GOG-0218 trial in patients with newly diagnosed advanced ovarian cancer. Avastin plus carboplatin and paclitaxel chemotherapy followed by Avastin maintenance therapy met...

Read the full 177 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >